B. Lindh

发表

Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.

H. Sorbye, C. Kersten, B. Glimelius, 2015, Clinical colorectal cancer.

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy

N. Loman, T. Hatschek, M. Söderberg, 2013, Medical Oncology.

A Population-based Study on the First Forty-Eight Breast Cancer Patients Receiving Trastuzumab (Herceptin®) on a Named Patient Basis in Sweden

J. Bergh, S. Klaar, L. Tennvall-Nittby, 2002, Acta oncologica.

Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment.

L. Beckman, R. Henriksson, M. Erlanson, 2004, European journal of cancer.

Anal cancer in Sweden 2015–2019. Implementation of guidelines, structural changes, national registry and early results

B. Zackrisson, E. Angenete, M. Lydrup, 2022, Acta oncologica.

Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines.

B. Glimelius, L. Balteskard, P. Pfeiffer, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers.

J. Bergh, L. Beckman, R. Henriksson, 2003, Clinical breast cancer.

p53 and vascular‐endothelial‐growth‐factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma

R. Henriksson, B. Linderholm, K. Grankvist, 2000, International journal of cancer.

Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial

M. Fernö, J. Bergh, N. Loman, 2012, Breast Cancer Research and Treatment.

A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.

J. Bergh, C. Blomqvist, H. Nordgren, 2007, European journal of cancer.

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival

M. Fernö, C. Perou, J. Bergh, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

p53 and vascular‐endothelial‐growth‐factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma

R. Henriksson, B. Linderholm, K. Grankvist, 2000, International journal of cancer.